Eisai's Banzel gets US approval and complete response letter for epilepsy
This article was originally published in Scrip
Executive Summary
Eisai'santiconvulsant Banzel (rufinamide) has received approval from the US FDA as an adjunctive treatment for of seizures associated with a severe form of epilepsy, Lennox-Gastaut syndrome (LGS), in patients aged four years and older. It will be launched in the US in 2009.